

ACTA DERMATO- VENEREOLOGICA

NEWSLETTER (October 2021)

Editors' Choice in October 2021 in Acta Dermato-Venereologica:

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry

Lieneke F.M. Ariëns, Daphne S. Bakker, Lotte S. Spekhorst, Jorien van der Schaft, Judith L. Thijs, Inge Haeck, Annebeth E. Flinterman, Marijke Kamsteeg, Marie L.A. Schuttelaar, Marjolein S. De Bruin-Weller



Lieneke F.M. Ariëns

Comments by the authors:

Research has shown that atopic dermatitis (AD) has a significant impact on work productivity with significantly higher absenteeism, presenteeism and overall work impairment in patients with inadequately controlled AD. Recent insight into the underlying immune pathogenesis of AD has led to the development of novel targeted therapies, with dupilumab as first registered biologic treatment for AD. The goal of this study was to examine the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a daily practice setting. Given the high costs characterizing new therapeutics, more insight on the indirect costs provides very relevant information.

[Read more](#)




Fig. 1. Weekly productivity and activity impairment (mean percent (standard deviation)) at baseline and after 52-weeks of treatment with dupilumab.

Further highlights of October:

Role of Mast Cells in the Pathogenesis of Pruritus in Mastocytosis. [Read more](#)

Dominika Kwiatkowska, Adam Reich

Interobserver Agreement on Dermoscopic Features and their Associations with In Situ and Invasive Cutaneous Melanomas. [Read more](#)

Sam Polesie, Lisa Sundback, Martin Gillstedt, Hannah Ceder, Johan Dahlén Gyllencreutz, Julia Fougelberg, Eva Johansson Backman, Jenna Pakka, Oscar Zaar, John Paoli

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study. [Read more](#)

Christopher Willy Schwarz, Nikolai Loft, Mads Kirchheiner Rasmussen, Christoffer V. Nissen, Tomas Norman Dam, Kawa Khaled Ajeiy, Alexander Egeberg, Lone Skov

Epidemiology, Comorbidity and Risk Factors for Psoriatic Arthritis: A Health Insurance Claims Database Analysis. [Read more](#)

Reinhardt Maximilian, Claudia Garbe, Jana Petersen, Matthias Augustin, Natalia Kirsten, Mona H.C. Biermann, Benjamin M. Häberle, Kristina Hagenström

Xerosis in Patients with Type 2 Diabetes: An Italian Multicentre Study. [Read more](#)

Luca Stingeni, Marta Tramontana, Lorenzo Cordera, Michela Castello, Aurora Parodi; Italian Diabetix Group

Screening for Body Dysmorphic Disorder among Patients Seeking Dermatological and Cosmetic Care: A Cross-sectional Study. [Read more](#)

Valérie Peeters, Sherief R. Janmohamed, Samira Baharlou, Jan Gutermuth, Ria Willemsen

All articles published in October 2021 in Acta Dermato-Venereologica are available [here](#)

Top citations (the most cited paper per publication year 2018–2020):

Year	Title and authors	Citations
2018	Clinical Characteristics of Pruritus and Pain in Patients with Hidradenitis Suppurativa <i>Łukasz Matusiak, Justyna Szczęch, Karolina Kaaz, Edyta Lelonek, Jacek C. Szepietowski</i>	48
2019	European S2k Guideline on Chronic Pruritus <i>Elke Weisshaar, Jacek C. Szepietowski, Florence J. Dalgard, Simone Garcovich, Uwe Gieler, Ana M. Giménez-Arnau, Julien Lambert, Tabi Leslie, Thomas Mettang, Laurent Misery, Ekin Şavk, Markus Streit, Erwin Tschachler, Erwin Tschachler, Joanna Wallengren, Sonja Ständer</i>	57
2020	Cutaneous Clinico-Pathological Findings in Three COVID-19-Positive Patients Observed in the Metropolitan Area of Milan, Italy <i>Raffaele Gianotti, Stefano Veraldi, Sebastiano Recalcati, Marco Cusini, Massimo Ghislanzoni, Francesca Boggio, Lindy P. Fox</i>	65

ActaDV on a new publication platform

We are excited to announce that Acta Dermato-Venereologica (ActaDV) has just transitioned publication system from our own internally developed system to a publicly supported system called Open Journal Systems (OJS).

The new publication platform affords ActaDV the opportunity to improve the quality and speed of our publication process as well as expand the reach of its published contents. Advantages that this change in system can offer ActaDV and its stakeholders include:

- Modernization and conformation to industry standards – OJS was designed specifically for open access, peer-reviewed publishing and supports for example JATS XML standardization, which has become the standard ‘model’ for journal articles. JATS XML is used in most scholarly communities today (including public archives like PubMed Central amongst other indexes and hosts).
- Increased reach of journal contents – by offering a platform that is optimized for content discovery across search engines such as Google, Google Scholar, and Bing, and that provides comprehensive indexing. In short, contents on the new platform will be machine-readable and searchable meaning they can more easily be accessed, read and indexed.
- Increased efficiency and transparency in the publication process - saving time and energy for both authors and the editorial team while maintaining integrity throughout the editorial process. By getting an end-to-end journal publishing and management system, all steps of the publication can be handled in the same system and a lot of what used to be manual work will now be automated. Hence the new system not only provides the technical infrastructure for the presentation of contents, but also the complete editorial-management workflow (including submission, peer-review, and indexing).
- Increased quality and security – by streamlining the record-keeping process, ActaDV can now offer an even more secure environment for archiving and stewardship of scholarly content.
- Continuous development – with more than 10,000 journals worldwide OJS is continuously being developed with new features being added as scholarly communication is developed.
- Improved user experience – many ActaDV authors already have an account with OJS and are familiar with the submission process.